# US 2003/0077256 A1 · Pancreas regeneration using embryonic pancreatic cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077256 A1
- Document ID: US20030077256A1
- Status: Published application
- Kind: A1
- Application number: 09/981,750
- Filed: 2001-10-19
- Published: 2003-04-24
- Earliest claimed: 2001-10-19
- Inventors: Paul Czernichow; Raphael Scharfmann
- Web page: https://patentgrep.com/patent/US20030077256A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 5/50: for increasing or potentiating the activity of insulin
- C12N 2510/04: Immortalised cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a method of regenerating pancreas function in an individual by transplantation of an effective amount of functional pancreatic cells derived from embryonic pancreatic cells not older than 10 weeks of development. Also provided is the method of producing functional animal pancreatic cell. The invention also provides a method of treatment of diabetics. Also are provided pancreatic beta cells as a medicament to treat diabetics.

## Claims

### Claim 1

A method of regenerating pancreas function in an individual, the method comprising
(a) introducing an effective amount of animal embryonic pancreatic cells not older than 10 weeks of development, into the kidney capsule of non-obese diabetic/severe combined immunodeficiency (NOD/scid) animal, excepted human, wherein said NOD/ scid is of a different species than said animal from which are obtained said embryonic pancreatic cells; and
(b) allowing the animal embryonic pancreatic cells to develop, to differentiate and to regenerate at least a pancreatic function; and
(c) transplantation of an effective amount of the animal functional pancreatic cells obtained at step (b), into said individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual is a mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammal is a human.

### Claim 4 (depends on 1)

The method of claim 1, wherein said animal embryonic pancreatic cells are human embryonic pancreatic cells.

### Claim 5 (depends on 4)

The method of claim 4, wherein said human embryonic pancreatic cells is of 6 to 9 weeks of development.

### Claim 6 (depends on 1)

The method of claim 1, wherein the non-obese diabetic/severe combined immunodeficiency animal is a mouse.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of the animal pancreatic cells transplanted at step (c) is comprised between about 103 to about 1012 animal pancreatic cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the animal pancreatic cells transplanted at step (c) are introduced into the pancreas of said individual.

### Claim 9 (depends on 1)

The method of claim 1, wherein said pancreatic function is the regulation of glycemia.

### Claim 10 (depends on 1)

The method of claim 1, wherein said individual is an insulin-dependant diabetic.

### Claim 11

A method of treatment of diabetes in a human patient in need of such treatment, the method comprising the steps of:
(a) introducing an effective amount of human embryonic pancreatic cells not older than 10 weeks of development, into the kidney capsule of non-obese diabetic/severe combined immunodeficiency (NOD/scid) animal, excepted human; and
(b) allowing the embryonic pancreatic cells to develop, to differentiate and to regenerate at least the pancreatic function; and
(c) transplantation of an effective amount of the human functional pancratic cells obtained at step (b), into said patient,
(d) and treating diabetics, wherein said treatment is effected by the regeneration of said pancreatic function of regulation of glycemia.

### Claim 12 (depends on 11)

The method of claim 11, wherein the non-obese diabetic/severe combined immunodeficiency animal is a mouse.

### Claim 13

A method of producing functional animal pancreatic cell wherein said method comprises the steps of:
(a) introducing an effective amount of animal embryonic pancreatic cells not older than 10 weeks of development, into the kidney capsule of non-obese diabetic/severe combined immunodeficiency (NOD/scid) animal, excepted human, wherein said NOD/scid is of a different species than said animal from which are obtained said embryonic pancreatic cells; and
(b) allowing the animal embryonic pancreatic cells to develop, to differentiate and to regenerate at least a pancreatic function; and
(c) collecting animal pancreatic cells obtained at step (b), and
(d) optionally in vitro culturing the cells obtained at step (c).
(e)optionally immortalizing the cells obtained at step (d)

### Claim 14 (depends on 13)

The method of claim 13, wherein said pancreatic function is the regulation of glycemia.

### Claim 15 (depends on 13)

Method according to claim 13 wherein said functional animal pancreatic cell is further genetically modified.

### Claim 16 (depends on 13)

Functional animal pancreatic cell obtained by the method according to claim 13 wherein said cell is a pancreatic beta cell.

### Claim 17 (depends on 1)

Pancreatic beta cell of claim 1, wherein said cell express insulin in response to glucose.

### Claim 18 (depends on 13)

Functional animal pancreatic cell obtained by the method according to claim 13 wherein said cell is immortalized with a virus or a variant or a fragment thereof, said virus being selected among lentivirus, Simian virus 40, Epstein-Bahr virus.

### Claim 19 (depends on 16, 17, 18)

Pancreatic cell according to claims 16 to 18 wherein said cell is a human cell.

### Claim 20 (depends on 19)

Pancreatic cell according to claim 19 as a medicament.

### Claim 21 (depends on 19)

Use of a pancreatic cell according to claim 19 for preparing a medicament to treat diabetics.

### Claim 22 (depends on 19)

Use of a pancreatic cell according to claim 19 for cell therapy.

### Claim 23 (depends on 19)

Use of a pancreatic cell according to claim 19 for studying the physiopathological development of diabetics.

### Claim 24

A method of producing animal pancreatic cell at different stages of development wherein said method comprises the steps of:
(a) introducing an effective amount of animal embryonic pancreatic cells not older than 10 weeks of development, into the kidney capsule of non-obese diabetic/severe combined immunodeficiency (NOD/scid) animal, excepted human, wherein said NOD/scid is of a different species than said animal from which are obtained said embryonic pancreatic cells; and
(b) allowing the animal embryonic pancreatic cells to develop, optionally to differentiate and optionally to regenerate at least a pancreatic function; and
(c) collecting animal pancreatic cells obtained at step (b) at different periods of time, and
(d) optionally in vitro culturing the cells obtained at step (c).
(e) optionally immortalizing the cells obtained at step (d).

### Claim 25 (depends on 24)

Use of pancreatic cells obtained by the method of claim 24 for studying pancreas development
